Astal Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 157295, "name": "Astal Lab", "stock_name": "Astal Lab", "full_name": "Astal Laboratories Ltd", "name_url": "stocks-analysis/astal-lab", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "72.70", "chg": -1.09, "chgp": "-1.48%", "dir": -1, "prev_price": "73.79", "mcapval": "311.00 Cr", "mcap": "Micro Cap", "scripcode": 512600, "symbol": "", "ind_name": "Trading & Distributors", "ind_code": 49, "indexname": "India SENSEX", "isin": "INE307N01014", "curr_date": "Mar 23", "curr_time": "", "bse_nse_vol": "49.31 k", "exc_status": "Active", "traded_date": "Mar 23, 2026", "traded_date_str": "2026 03 23", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astal-lab-157295-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Astal Laboratories Ltd Falls to 52-Week Low of Rs 69.01 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-stock-falls-to-52-week-low-of-rs6901-3907557", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_priceRelatedfactors_3907557.png", "date": "2026-03-23 11:42:40", "description": "A sharp decline in Astal Laboratories Ltd shares has pushed the stock to a fresh 52-week low of Rs 69.01 on 23 Mar 2026, marking a significant 33% drop from its 52-week high of Rs 103.20. This downturn comes amid broader market weakness, but the stock’s underperformance relative to its sector and benchmark indices highlights company-specific pressures." }, { "title": "Astal Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-sell-3905981", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_mojoScore_3905981.png", "date": "2026-03-22 10:10:13", "description": "Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Astal Laboratories Ltd Falls to 52-Week Low of Rs.69.84 Amid Market Downturn", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-falls-to-52-week-low-of-rs6984-amid-market-downturn-3900590", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_priceRelatedfactors_3900590.png", "date": "2026-03-19 13:35:05", "description": "Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, touched a fresh 52-week low of Rs.69.84 today, marking a significant decline amid broader market weakness and sectoral underperformance. The stock’s recent price action reflects ongoing pressures despite some positive financial metrics reported over the past year." }, { "title": "Astal Laboratories Ltd Falls to 52-Week Low of Rs.70 Amidst Market Headwinds", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-falls-to-52-week-low-of-rs70-amidst-market-headwinds-3894329", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_priceRelatedfactors_3894329.png", "date": "2026-03-16 15:41:17", "description": "Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has touched a new 52-week low of Rs.70 today, marking a significant price level for the stock amid a mixed market environment." }, { "title": "Astal Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-sell-3884924", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_mojoScore_3884924.png", "date": "2026-03-11 10:10:17", "description": "Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook." }, { "title": "Astal Laboratories Ltd Falls to 52-Week Low of Rs.70.1 Amid Market Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-falls-to-52-week-low-of-rs701-amid-market-pressure-3864477", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_priceRelatedfactors_3864477.png", "date": "2026-03-02 11:04:11", "description": "Astal Laboratories Ltd, a player in the Trading & Distributors sector, recorded a fresh 52-week low today at Rs.70.1, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s recent performance reflects a continuation of downward momentum, with notable implications for its valuation and comparative market standing." }, { "title": "Astal Laboratories Ltd Declines 0.42% Despite Quality Upgrade: 3 Key Factors Behind the Week’s Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-declines-042-despite-quality-upgrade-3-key-factors-behind-the-weeks-moves-3863261", "imagepath": "", "date": "2026-03-01 15:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Feb:</strong> Quality grade upgraded from below average to average</p>\n <p><strong>17 Feb:</strong> Mojo Grade upgraded from Strong Sell to Sell amid strong Q3 FY26 results</p>\n <p><strong>17 Feb:</strong> Stock price rebounds sharply by 7.25% after two days of decline</p>\n <p><strong>20 Feb:</strong> Week closes at Rs.79.00, down 0.42% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.79.33</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div..." }, { "title": "Astal Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-sell-3862152", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_mojoScore_3862152.png", "date": "2026-02-28 10:10:03", "description": "Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Astal Laboratories Q3 FY26: Growth Momentum Masks Alarming Margin Erosion", "link": "https://www.marketsmojo.com/news/result-analysis/astal-laboratories-q3-fy26-growth-momentum-masks-alarming-margin-erosion-3844511", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_quaterlyResult_3844511.png", "date": "2026-02-17 11:32:12", "description": "Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20." } ], "total": 132, "sid": "157295", "stock_news_url": "https://www.marketsmojo.com/news/astal-laboratories-157295" }, "announcements": [ { "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011", "datetime": "20-Mar-2026", "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aceso Research Labs LLP", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015", "datetime": "19-Mar-2026", "details": "Submission of Intimation under Regulation 7 (2) of SEBI (PIT) Regulations 2015.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "16-Feb-2026", "details": "Submission of newspaper publication.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

16 Feb: Quality grade upgraded from below average to average

17 Feb: Mojo Grade upgraded from Strong Sell to Sell amid strong Q3 FY26 results

17 Feb: Stock price rebounds sharply by 7.25% after two days of decline

20 Feb: Week closes at Rs.79.00, down 0.42% for the week

Week Open

Rs.79.33

Week CloseRead full news article

Astal Laboratories Ltd is Rated Sell

2026-02-28 10:10:03

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Astal Laboratories Q3 FY26: Growth Momentum Masks Alarming Margin Erosion

2026-02-17 11:32:12

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20.

Read full news article